Näytä tiedotekategoriat

Etusivu » Tiedotteet » Terveys » CHMP:ltä positiivinen kanta ADCETRIS –lääkkeen käyttöalueen laajennukselle

Takeda Oy

CHMP:ltä positiivinen kanta ADCETRIS –lääkkeen käyttöalueen laajennukselle

Julkaistu: 31.05.2016 klo 11:06
Julkaisija: Takeda Oy

Euroopan Lääkeviraston EMA:n lääkevalmistekomitea (Committee for Medicinal Products for Human Use, CHMP) on ilmaissut myönteisen kantansa ADCETRIS -lääkkeen (brentuksimabivedotiini) käyttöön sellaisten Hodgkinin lymfoomaa sairastavien potilaiden hoidossa, joilla taudin uusiutumisen riski autologisen kantasolusiirron jälkeen on suurentunut. Tämä käyttöalueen esitetty laajennus perustuu faasin 3 AETHERA -tutkimukseen, joka osoitti ADCETRIS -hoidon pidentävän merkitsevästi Hodgkinin lymfoomaa sairastavien potilaiden etenemisvapaata elossaoloaikaa konsolidaatiohoitona autologisen kantasolusiirron jälkeen.



Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) asConsolidation Treatment in Post-Transplant Hodgkin Lymphoma


  • Positive opinion reinforces the role of ADCETRIS in earlier line of treatment in Hodgkin lymphoma
  • Opinion based on pivotal AETHERA study investigating brentuximab vedotin (plus best supportive care) following transplant vs placebo (plus best supportive care)


Cambridge, Mass. and Osaka, Japan, [May 27], 2016 – Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the extension of the current conditional approval of ADCETRIS® (brentuximab vedotin) and recommended its approval for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplantation (ASCT). On average 50 percent of Hodgkin lymphoma patients relapse after ASCT and those patients with additional risk factors can be at even higher risk of relapse. ADCETRIS would be the first agent to be approved for European patients in this setting, where currently no therapeutic options exist.


“While ASCT is the standard of care following failure of frontline chemotherapy in Hodgkin lymphoma, we know that many patients will unfortunately see their disease return. Early eradication of residual disease through treatment with ADCETRIS has a high chance of preventing the disease from returning in these patients,” said Dirk Huebner, M.D., Executive Medical Director, Oncology Therapeutic Area Unit, Takeda Pharmaceutical Company. “If approved by the European Commission, ADCETRIS may offer a new way for physicians to consolidate disease remission after ASCT in Hodgkin lymphoma.”


This opinion is based on efficacy and safety results from the Phase 3 AETHERA study. The AETHERA trial met its primary endpoint with ADCETRIS (plus best supportive care) treatment resulting in a statistically significant improvement in progression-free survival (PFS) versus placebo (plus best supportive care) as assessed by an independent central review committee (hazard ratio=0.57; p-value=0.001), which equates to a 75 percent improvement in PFS. PFS was assessed after a minimum of two years post initiation of treatment for all study patients.


An updated analysis conducted after three years of follow up showed sustained PFS improvement (per Independent Review Facility; HR=0.58; 95%CI (0.41,0.81). A pre-specified interim analysis of overall survival showed no statistically significant difference between the treatment arms. The safety profile of ADCETRIS in the AETHERA trial was generally consistent with the existing prescribing information, with the exception of peripheral neuropathy, which was higher.


The CHMP positive opinion for ADCETRIS will now be reviewed by the European Commission (EC). If the CHMP recommendation is formally adopted by the EC, which has the authority to approve medicines for the  European Union (EU), ADCETRIS will be approved for marketing of this indication in the 28 member states of the EU, Norway Liechtenstein and Iceland.


About Hodgkin Lymphoma
Lymphoma is a general term for a group of cancers that originate in the lymphatic system. There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Hodgkin lymphoma is distinguished from other types of lymphoma by the presence of one characteristic type of cell, known as the Reed-Sternberg cell. The Reed-Sternberg cell expresses CD30.


ADCETRIS® (brentuximab vedotin) is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing proprietary technology by Seattle Genetics. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

ADCETRIS was granted conditional marketing authorization by the European Commission in October 2012 for two indications: (1) for the treatment of adult patients with relapsed or refractory CD30-positive Hodgkin lymphoma following autologous stem cell transplant (ASCT), or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option, and (2) the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). In January 2016, the European Commission approved a Type II variation to include data on the retreatment of adult patients with Hodgkin lymphoma or sALCL who previously responded to ADCETRIS and who later relapse. ADCETRIS has received marketing authorization by regulatory authorities in more than 60 countries.

ADCETRIS is being evaluated broadly in more than 45 ongoing clinical trials, including the Phase 3 ALCANZA trial in CD30+ cutaneous T cell lymphoma (CTCL) and two additional Phase 3 studies, one in frontline classical Hodgkin lymphoma (ECHELON-1) and one in frontline CD30+ mature T-cell lymphomas (ECHELON-2), as well as trials in many additional types of CD30-expressing malignancies.

Seattle Genetics and Takeda are jointly developing ADCETRIS. Under the terms of the collaboration agreement, Seattle Genetics has U.S. and Canadian commercialization rights and Takeda has rights to commercialize ADCETRIS in the rest of the world. Seattle Genetics and Takeda are funding joint development costs for ADCETRIS on a 50:50 basis, except in Japan where Takeda is solely responsible for development costs.


About Takeda Pharmaceutical Company

Takeda Pharmaceutical Company Limited is a global, R&D-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its research efforts on oncology, gastroenterology and central nervous system therapeutic areas. It also has specific development programs in specialty cardiovascular diseases as well as late-stage candidates for vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as its presence in emerging markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit http://www.takeda.com/news.


Additional information about Takeda is available through its corporate website, www.takeda.com, and additional information about Takeda Oncology, the brand for the global oncology business unit of Takeda Pharmaceutical Company Limited, is available through its website, www.takedaoncology.com.




ADCETRIS® is currently indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL):

1. following autologous stem cell transplant (ASCT) or

2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.


ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).



European Media

Kate Burd

kate.burd@takeda.com +44 7974 151510

Media   outside Japan/EU

Amy Atwood

amy.atwood@takeda.com +1-617-444-2147


Japanese Media

Tsuyoshi Tada

tsuyoshi.tada@takeda.com +81 (0) 3-3278-2417


Tietoja Takedasta

Takeda on tutkimukseen keskittyvä maailmanlaajuinen yritys, jonka toiminta painottuu lääkealalle. Sen pääkonttori sijaitsee Osakassa, Japanissa. Takeda on Japanin suurin lääkeyritys ja yksi alan suurista toimijoista maailmanlaajuisesti ja se on sitoutunut tavoittelemaan parempaa elämänlaatua johtavilla lääke-innovaatioilla. Takeda tutkimustoiminta keskittyy onkologian, gastroenterologian ja keskushermosto-sairauksien alueille. Sillä on myös tuotekehitysprojketeja erikoishoitoa vaativiin sydän-ja verenkiertosairauksiin sekä myöhäisen kehitysvaiheen rokotetuotteita. Takeda tekee tutkimus ja tuotekehitystä itsenäisesti ja yhteistyössä kumppaneiden kanssa. Takedan kasvua ja kehitystä vauhdittavat erityisesti uudet innovatiiset tuotteet onkologian ja gastroenterologian alueilla, sekä läsnäolo kehittyvillä markkinoilla. Takedan yli 30 000 työntekijää ovat sitoutuneita parantamaan potiulaiden elämänlaatua ja työskentelemään kumppaneiden kanssa terveydenhoidon alalla yli 70 maassa.


Lisätietoja Takedasta konsernin verkkosivuilta www.takeda.com. / http://www.takeda.com/news ja www.takedaoncology.com




Japanese Media

Tsuyoshi Tada


+81 (0) 3-3278-2417

Media outside Japan

Amy Atwood



Julkaisijan muita tiedotteita

Hae kategoriasta

Kategorian julkaisijoita

Kategorian uusimmat

ePressin asiakkaita
Trafi Radisson Blu Tellabs